GLP-1 Agonist Comparison Matrix
Overview
A side-by-side comparison of the three incretin-based agonists in this database — Tirzepatide (dual GIP/GLP-1), Retatrutide (triple GIP/GLP-1/glucagon) and Semaglutide (selective GLP-1) — across chemistry, receptor pharmacology, pharmacokinetics, safety and research positioning.
Overview
| Feature | Tirzepatide | Retatrutide | Semaglutide |
|---|---|---|---|
| Class | GIP/GLP-1 dual | GIP/GLP-1/GCGR triple | Selective GLP-1 |
| Originator | Eli Lilly | Eli Lilly | Novo Nordisk |
| Development status | Marketed / studied | Investigational (Phase 3) | Marketed / studied |
| Study route | SC weekly | SC weekly | SC weekly / oral daily |
| Half-life | ≈ 5 days | ≈ 6 days | ≈ 7 days |
Chemical Comparison
| Property | Tirzepatide | Retatrutide | Semaglutide |
|---|---|---|---|
| CAS number | 2023788-19-2 | 2381089-83-3 | 910463-68-2 |
| Molecular formula | C₂₂₅H₃₄₈N₄₈O₆₈ | ≈ C₂₂₈H₃₅₄N₄₆O₆₈ | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular weight | 4813.45 | ≈ 4840.58 | 4113.58 |
| Sequence length | 39 aa | 39 aa | 31 aa |
| Fatty-acid modification | C20 diacid | C20 diacid | C18 diacid |
| Purity (HPLC) | ≥ 98% | ≥ 98% | ≥ 98% |
Receptor Pharmacology Comparison
| Receptor | Tirzepatide | Retatrutide | Semaglutide |
|---|---|---|---|
| GLP-1R | Active | Active | Active |
| GIPR | Active | Active | Inactive |
| Glucagon receptor (GCGR) | Inactive | Active | Inactive |
| Profile | Balanced GIP/GLP-1 | Balanced triple | Selective GLP-1 |
Pharmacokinetic Comparison
| Parameter | Tirzepatide | Retatrutide | Semaglutide |
|---|---|---|---|
| Bioavailability (SC) | ≈ 80% | ≈ 75% | ≈ 89% |
| Tmax | 8–24 h | 12–24 h | 12–24 h |
| Volume of distribution | ≈ 0.3 L/kg | ≈ 0.25 L/kg | ≈ 0.3 L/kg |
| Protein binding | ≈ 99% | ≈ 99% | ≈ 99% |
| Metabolism | Proteolytic | Proteolytic | Proteolytic |
| Elimination | Renal / fecal | Renal / fecal | Renal / fecal |
Research Evidence Comparison
A qualitative view of research focus and positioning (research context; specific numerical outcomes are not restated as claims):
| Research area | Tirzepatide | Retatrutide | Semaglutide |
|---|---|---|---|
| Type-2-diabetes research | Extensive | Emerging (Phase 2/3) | Extensive |
| Obesity / body-weight research | Extensive | Active (Phase 2/3) | Extensive |
| Cardiovascular-outcome research | Ongoing | Early | Extensive |
| Glucagon-receptor (energy expenditure) | No | Yes (defining feature) | No |
| Oral-route research | No | No | Yes |
Safety Profile Comparison
Published safety observations, provided as research reference only; none of these compounds is for human or veterinary use.
| Observation | Tirzepatide | Retatrutide | Semaglutide |
|---|---|---|---|
| GI tolerability | Dose-dependent GI events | Dose-dependent GI events | Dose-dependent GI events |
| Pancreatitis / gallbladder | Low frequency | Low frequency | Low frequency |
| Heart-rate increase | Reported | Reported | Reported |
| Thyroid C-cell (rodent) | Yes (class effect) | Yes (class effect) | Yes (class effect) |
Dosing Comparison (Research)
Reconstitution-oriented reference ranges from the literature; not human dosing guidance.
| Parameter | Tirzepatide | Retatrutide | Semaglutide |
|---|---|---|---|
| Research range (weekly, SC) | 0.25–2.0 mg | 0.25–1.2 mg | 0.25–2.4 mg |
| Escalation interval | ≈ 4 weeks | ≈ 4 weeks | ≈ 4 weeks |
| Route | SC | SC | SC / oral |
Selection Considerations
Choose Tirzepatide when
The research needs both GIP and GLP-1 activation, or a head-to-head against selective GLP-1 agonism.
Choose Retatrutide when
Triple activation is the point — especially the glucagon-receptor contribution to energy expenditure.
Choose Semaglutide when
A well-characterized selective GLP-1 agonist is needed, or the study focuses on cardiovascular outcomes or the oral route.
Analytical Method Comparison
| Parameter | Tirzepatide | Retatrutide | Semaglutide |
|---|---|---|---|
| HPLC gradient | 20–60% B | 25–65% B | 20–60% B |
| Column | C18 (4.6 × 250 mm) | C18 (4.6 × 250 mm) | C18 (4.6 × 250 mm) |
| Detection | UV 214 nm | UV 214 nm | UV 214 nm |
| MS ionization | ESI+ | ESI+ | ESI+ |
| Charge states | ≈ +4 to +8 | ≈ +4 to +8 | ≈ +3 to +7 |
Selected References
- Coskun T, et al. Dual GIP/GLP-1 agonist tirzepatide. Diabetes, 2018.
- Coskun T, et al. Triple GIP/GLP-1/glucagon agonist retatrutide. Nature Metabolism, 2022.
- Frías JP, et al. Tirzepatide versus semaglutide (SURPASS-2). The Lancet, 2021.
- Marso SP, et al. Semaglutide and cardiovascular outcomes (SUSTAIN-6). New England Journal of Medicine, 2016.
- Wilding JPH, et al. Once-weekly semaglutide for obesity (STEP-1). New England Journal of Medicine, 2021.
Quality & Supply
- All three agonists available research-grade, HPLC-characterized with a Certificate of Analysis per batch
- Identity confirmed by LC-MS; endotoxin tested by LAL
- Research samples through to bulk, with worldwide delivery
- Custom quantities and packaging on request
Need GLP-1 Agonist Comparison Matrix — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
